{"disease":{"id":"high-risk-prostate-carcinoma","name":"high risk prostate carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05004285","title":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":398,"lead_sponsor_name":"FutureChem","has_results":false},{"nct_id":"NCT06204341","title":"Towards Optimal Treatment for High Risk Prostate Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":207,"lead_sponsor_name":"Haaglanden Medical Centre","has_results":false},{"nct_id":"NCT07054346","title":"Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT02160353","title":"Neo-adjuvant Abiraterone Prostate Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Cancer Trials Ireland","has_results":false},{"nct_id":"NCT06461793","title":"Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06384222","title":"Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Ivan de Kouchkovsky, MD","has_results":false},{"nct_id":"NCT05437679","title":"Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System","phase":"","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Angle plc","has_results":false},{"nct_id":"NCT06388369","title":"Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT06528210","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}